FILTER

Refine your search with the following facets to narrow down your results.

8 Current news of Abraxis BioScience

Celgene Completes Acquisition of Abraxis

19-Oct-2010 - Celgene Corporation announced it has completed its acquisition of Abraxis BioScience, Inc. For each share of Abraxis common stock, Abraxis shareholders will receive $58.00 in cash, 0.2617 shares of Celgene common stock, and one tradeable Contingent Value Right (CVR), which entitles its holder to ...

albumin oncology tumors

Abraxis BioScience And Specialised Therapeutics Announce Approval To Market ABRAXANE For Metastatic Breast Cancer In New Zealand

02-Aug-2010 - Abraxis BioScience, Inc. and Specialised Therapeutics Ltd. announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of ...

breast cancer medical devices New Zealand

Study shows breast cancer drug ABRAXANE increases survival time for advanced pancreatic cancer

18-May-2010 - An international study of cancer drug ABRAXANE ® (nanoparticle albumin-bound paclitaxel) has shown promising results for patients with advanced pancreatic cancer when used in combination with Gemcitabine. Abraxis BioScience, Inc.announced findings from the phase I/II study, which showed ...

biomarker breast cancer melanoma +1

ABRAXANE meets primary endpoint in phase 3 trial for advanced non-small cell lung cancer

19-Mar-2010 - An international lung cancer trial has shown positive results in those patients treated with leading breast cancer drug ABRAXANE® in combination with carboplatin. Biopharmaceutical companies Abraxis Bioscience Inc and Specialised Therapeutics Australia Pty Ltd (STA) announced that the extensive ...

breast cancer chemotherapy clinical trials +1

Prometic announces agreement to commercialize prion capture technology

07-Jan-2010 - ProMetic Life Sciences Inc. announced that it has entered into a collaboration agreement with Abraxis BioScience, Inc. to develop and commercialize various applications deriving from ProMetic's prion capture technology platform. As part of the Agreement, Abraxis and ProMetic will equally share ...

plasma

ABRAXANE Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma

10-Nov-2009 - Abraxis BioScience, Inc. announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) ...

chemotherapy clinical trials food +5

Abraxis BioScience Names Mary Lynne Hedley, Ph.D., Executive Vice President of Operations and Chief Scientific Officer

14-Jul-2009 - Abraxis BioScience, Inc. announced that Mary Lynne Hedley, Ph.D. has been appointed Executive Vice President of Operations and Chief Scientific Officer. Dr. Hedley most recently served as Executive Vice President of Eisai Corporation of North America following Eisai’s acquisition of MGI PHARMA, ...

biotechnology immunology patents

ABRAXANE demonstrates longer progression-free survival versus Taxotere in the treatment of first-line metastatic breast cancer

05-Jun-2007 - Abraxis BioScience, Inc. announced the presentation of updated results from an ongoing open-label, randomized head-to-head Phase II clinical trial comparing ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) and Taxotere(R) ...

breast cancer clinical trials food +1